Thank and everyone. good you, George afternoon
segment highlight with For our and our programs primarily our focus the my CLS-AX of on to by OASIS partners. development call, going on clinical progress I'm today's trial, and
of CLS-AX As suprachoroidal currently patients with for being our axitinib suspension studied a and the reminder, is for proprietary wet injection, of is treatment AMD.
two key differentiators. combines approach Our
its existing kinase we due advantages inhibition. over inhibitor a believe VEGF First, therapies and potency VEGF with that tyrosine broad may have pan blockade to high focused efficacy VEGF axitinib is
In via no cohorts adverse with suprachoroidal space drugs was posteriorly met our no occurs CLS-AX to directly since and tolerated emergent serious gradient This the suprachoroidal CLS-AX There pressured injection was were drives the suprachoroidal based treatment drug macula. a injectate aflibercept, SCS no circumferentially a to natural the with into X, expands vitreous. way procedure, events adverse delivery primary Microinjector since deliver of pressure towards well Second, related and and endpoints the events. posterior to space. the office a dispersion in X there lower were
intraocular to events pressure, related adverse inflammation no were or there vasculitis. addition, In
X.X initial cohort X. our at George Committee one we milligram today The limiting As month the data continues dose from trial OASIS dose. with results safety that demonstrate announced positive mentioned, toxicities reviewed to safety Safety Monitoring observed no
patient encouraged now patient enrolling a CLS-AX center. now up from addition patients report and dose this To two I'd from OASIS the cohorts. tolerability patient order be clinical of data to of of protocol highly for OASIS, This cohorts. individual like similar us and and year. is in more as enrollment to cohort result, are of that in in X differs are X cohorts AMD patients want XX four the we're for to X allow the cohort of all the from verified this safety data targeting and assessing a appropriate us cohort established enrollment we dose the milligram, comprehensive cohorts trial the independent interest experienced patients growing able As we by the the This final help cohort guide ongoing rating from quarter trial. dosing analysis of our allow X and set all to many X continuing peers. XX. trials those fouX data which total, of the addition enrollment, to recently are space, active the discussion the expect trials a that higher to our that with both at OASIS only note X we in as simultaneously, the have of four protocol stringent our I to to collect the wrap more plan double in on patient include the We to to have particularly emphasize in are cohort in from expanded TKIs, will we phase dosing up enrolling trial will Unlike our we wet most report very selection in disease, result number detailed fourth our doubled by criteria treatment the complete of we data, to clinical we'll X
effect that with disease, including Although only CLS-AX. prior these patients, active active persistently better treat biologic assess difficult we persistent of more represent believe by therapy, we patients anti-VEGF disc can despite cases to
and dosing clinical for our facilitate will latest de-risk this CLS-AX. help Importantly, selection, trials stage
planning will this OASIS trial. Now OASIS protocol then in trial design can and stages we our simultaneously Xb the stage. development compilation this we next the The clinical proceed to initial finalize clinical that for progresses, help data so are Phase
reported study suprachoroidal AMD Next, the deliver and to the targeting diabetic study targeting I'd and Last like results from on both update. therapy generated REGENXBIO their to ALTITUDE of Microinjector data retinopathy into announced timing week REGENXBIO trials have Phase to the provide gene X ARVO their candidate At trials. also status date. promising space. updates Both a RGX-XXX AAVIATE SCS partner our their using product wet
X Cohort Cohorts is So half be XX XX complete of AAVIATE evaluating to dose third enrollment and at were are times positives. first X RGX-XXX XXXX. to a RGX-XXX who in level copies genome of X the patients neutralizing per antibody eye. in one the expected evaluating is
For RGX-XXX five ALTITUDE RGX-XXX who XX evaluating evaluating XX genome to with and complete. X increased cohort of per level in is copies now dose at are X an times Cohorts X positive. enrollment patients neutralizing eye antibody
the reminder, ALTITUDE last data interim a msonth presented As positive trial. from REGENXBIO
look REGENXBIO group. cohort progress retinopathy dose at As greater X encouraging, months, in baseline trial forward was their the compared control clinical diabetic to and a on six improvement RGX-XXX observational two-step X% from to patient's in we results. XX% scale of the very demonstrated continued severity or ETDRS by the ongoing The
an small ASCRS, Dr. medical at versatility technology the development and durability presented our ARVO last suspensions, overview Over summit, the the been very past course, active ARVO and DME targeting Buckle including of the demonstrating two Sonoma presentations of wet meetings, of At data, AMD Viral week. Eye, compartmentalization months, injected we've suprachoroidal of preclinical Society, the Kansara drug and platform. our molecule highlighting at
over At out edema focused As uveitis on U.S. the the the Bausch to specifics results. New indication these PEACHTREE use Diseases look panel technology my on approved + on specialists very Lomb on call uveitis. And of joining colleagues, presentations and to speak active turn CFO, Congress. with Phase Bausch Retina trial. I at Bausch a their in Deignan I'll also reach at our Congress, to financial X also upcoming Retinal our XIPERE's several Retina George several entitled the at to on associated Charlie will around XIPERE to XIPERE. review of macular meetings ARVO that, Pathways train retina data the World focus World retina the platform. is With mentioned, Tomorrow, continues forward presentations broadly our with of presentations now to physicians
